Dr. Burzynski and His Discovery
Dr. Burzynski earned his medical degree with highest honors in 1967, in Poland, at the age of 24. He was the first in his class of 250 students. The next year, he received another doctorate, a PhD in biochemistry. He was one of the youngest persons in the history of Poland to receive both advanced degrees.
In 1967, Dr. Burzynski identified naturally occurring peptides in the human body that he concluded control the growth of cancer. He found a marked deficiency of these peptides in patients with cancer.
Dr. Burzynski came to the United States in 1970 and worked on these peptide fractions at Baylor College of Medicine in Houston, Texas, where he was a researcher and an Assistant Professor.
In 1977, Dr. Burzynski opened his clinic in Houston, where he since has been successfully using antineoplastons to treat patients who are in the last stages of cancer.
Dr. Burzynski has authored 175 scientific papers on antineoplastons, has presented scientific papers at major international conventions, and has been awarded 121 patents covering 38 countries for antineoplastons.
Currently, about 250 publications have been written on antineoplastons by researchers working independently of Dr. Burzynski.
Antineoplastons are peptides, amino acid derivatives, and organic acids produced by the body.
Because antineoplastons are harmless to healthy cells, the human body can be flooded with them, and only the cancer cells are affected.
Antineoplastons are produced synthetically at Dr. Burzynski's pharmaceutical facility in Texas.
For over 20 years, over 3,000 patients have received Dr. Burzynski's treatment. See patients' stories.
The Burzynski Clinic, Manufacturing Facility, and Research Institute
Dr. Burzynski employs about 120 people, 18 of whom are medical doctors and 7 of whom have earned doctorates in other fields.
The overhead costs of running the Clinic, manufacturing facility, and Institute equal millions of dollars each year.
At the Clinic, 74 clinical trials are underway, 72 for cancer, 1 for autoimmune disease, and 1 for HIV infection.
In 1991, a team from the NCI confirmed the anticancer activity of antineoplastons and verified five complete remissions of the 7 cases they evaluated.
The FDA requires extensive documentation of patient data and strict adherence to FDA rules and regulations for the clinical trials.
The manufacturing facility has been in operation since 1983 and has been upgraded throughout the years.
In 1998, the plant produced 24 metric tons of active ingredients.
The manufacture of antineoplastons is strictly regulated by the US government and must meet the same standards as must drugs made by large pharmaceutical companies.
The FDA, NCI, and independent consultants have verified that the manufacturing facility is in compliance with government regulations.
The FDA has thoroughly reviewed and approved the specifications for all drugs produced at the plant and all the quality control methods and procedures.
Research is ongoing at the Institute where scientists are working to screen new compounds for anticancer activity.
Scientists at the Institute are also working to understand the detailed mechanism of action of antineoplastons.